Arlene Berman

3.7k total citations
47 papers, 2.4k citations indexed

About

Arlene Berman is a scholar working on Oncology, Molecular Biology and Neurology. According to data from OpenAlex, Arlene Berman has authored 47 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 13 papers in Molecular Biology and 13 papers in Neurology. Recurrent topics in Arlene Berman's work include Cancer Treatment and Pharmacology (20 papers), Myasthenia Gravis and Thymoma (13 papers) and HER2/EGFR in Cancer Research (9 papers). Arlene Berman is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Myasthenia Gravis and Thymoma (13 papers) and HER2/EGFR in Cancer Research (9 papers). Arlene Berman collaborates with scholars based in United States, Malaysia and India. Arlene Berman's co-authors include Sandra M. Swain, Seth M. Steinberg, Jennifer A. Low, Catherine K. Chow, David N. Danforth, Arun Rajan, Sherry X. Yang, Neelima Denduluri, Giuseppe Giaccone and Janice M. Walshe and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Arlene Berman

47 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arlene Berman United States	22	1.3k	614	534	474	438	47	2.4k
Iacopo Petrini Italy	27	1.0k 0.8×	884 1.4×	688 1.3×	723 1.5×	504 1.2×	91	2.5k
Haruhiro Yukiue Japan	29	812 0.6×	839 1.4×	352 0.7×	1.1k 2.2×	300 0.7×	71	2.0k
Laura Boldrini Italy	27	916 0.7×	1.2k 1.9×	652 1.2×	733 1.5×	189 0.4×	98	2.5k
Chih‐Yi Hsu Taiwan	24	478 0.4×	979 1.6×	527 1.0×	355 0.7×	235 0.5×	92	2.0k
Vincenzo Damiano Italy	26	1.9k 1.5×	1.4k 2.2×	459 0.9×	1.2k 2.4×	155 0.4×	62	3.2k
Scott Cruickshank United States	21	1.2k 0.9×	741 1.2×	368 0.7×	1.0k 2.2×	220 0.5×	56	2.6k
Bing Liao China	22	371 0.3×	670 1.1×	444 0.8×	301 0.6×	252 0.6×	71	1.9k
Giuseppe Badalamenti Italy	25	1.0k 0.8×	621 1.0×	553 1.0×	764 1.6×	142 0.3×	144	2.3k
Nils D. Arvold United States	26	1.3k 1.0×	605 1.0×	709 1.3×	1.5k 3.2×	359 0.8×	67	3.3k
Raushan T. Kurmasheva United States	27	814 0.6×	1.3k 2.2×	366 0.7×	546 1.2×	315 0.7×	120	2.3k

Countries citing papers authored by Arlene Berman

Since Specialization

Citations

This map shows the geographic impact of Arlene Berman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arlene Berman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arlene Berman more than expected).

Fields of papers citing papers by Arlene Berman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arlene Berman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arlene Berman. The network helps show where Arlene Berman may publish in the future.

Co-authorship network of co-authors of Arlene Berman

This figure shows the co-authorship network connecting the top 25 collaborators of Arlene Berman. A scholar is included among the top collaborators of Arlene Berman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arlene Berman. Arlene Berman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Holtzman, Noa G., Annie Im, Arlene Berman, et al.. (2023). Baricitinib for Refractory Chronic Graft-Versus-Host Disease (cGVHD): Results of a Phase 1/2 Study. Transplantation and Cellular Therapy. 29(2). S251–S252. 1 indexed citations

Rajan, Arun, Chul Kim, Udayan Guha, et al.. (2017). OA18.02 Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma. Journal of Thoracic Oncology. 12(1). S313–S314. 6 indexed citations

Rajan, Arun, Christopher R. Heery, Andrew L. Mammen, et al.. (2016). Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).. Journal of Clinical Oncology. 34(15_suppl). e20106–e20106. 7 indexed citations

Thomas, Anish, Yuanbin Chen, Arlene Berman, et al.. (2016). Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer. 101. 104–110. 15 indexed citations

Goey, Andrew K.L., Tristan M. Sissung, Cody J. Peer, et al.. (2015). Abstract 5480: Effects of UGT1A1 genotype on pharmacokinetics and toxicities of belinostat administered by continuous infusion in two clinical trials. Cancer Research. 75(15_Supplement). 5480–5480. 1 indexed citations

Thomas, Anish, Arun Rajan, Arlene Berman, et al.. (2015). Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet Oncology. 16(2). 177–186. 197 indexed citations

Rajan, Arun, Corey A. Carter, Arlene Berman, et al.. (2014). Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. The Lancet Oncology. 15(2). 191–200. 99 indexed citations

Thomas, Anish, Esther Mena, Karen Kurdziel, et al.. (2013). 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors. Clinical Cancer Research. 19(6). 1487–1493. 19 indexed citations

Roy‐Chowdhuri, Sinchita, Liqiang Xi, Trinh Pham, et al.. (2011). EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Modern Pathology. 25(4). 548–555. 56 indexed citations

10.

Portera, Chia C., Janice M. Walshe, Douglas R. Rosing, et al.. (2008). Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Clinical Cancer Research. 14(9). 2710–2716. 125 indexed citations

11.

Walshe, Janice M., Arlene Berman, Seth M. Steinberg, et al.. (2006). A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Research and Treatment. 103(2). 177–183. 31 indexed citations

12.

Denduluri, Neelima, James J. Lee, Janice M. Walshe, et al.. (2006). Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Investigational New Drugs. 25(1). 63–67. 38 indexed citations

13.

Walshe, Janice M., Neelima Denduluri, Arlene Berman, Douglas R. Rosing, & Sandra M. Swain. (2006). A Phase II Trial with Trastuzumab and Pertuzumab in Patients with HER2-Overexpressed Locally Advanced and Metastatic Breast Cancer. Clinical Breast Cancer. 6(6). 535–539. 32 indexed citations

14.

Lee, James J., et al.. (2006). Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone. Journal of Clinical Oncology. 24(13). 2084–2091. 39 indexed citations

15.

Denduluri, Neelima, Antoinette R. Tan, Janice M. Walshe, et al.. (2005). A Pilot Study to Evaluate the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor AZD2171 and Chemotherapy in Locally Advanced and Inflammatory Breast Cancer. Clinical Breast Cancer. 6(5). 460–463. 4 indexed citations

16.

Wedam, Suparna, Jennifer A. Low, Xiao‐Sheng Yang, et al.. (2004). A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer. Journal of Clinical Oncology. 22(14_suppl). 578–578. 4 indexed citations

17.

Leonard, Gregory D., Jennifer A. Low, Arlene Berman, & Sandra M. Swain. (2004). CA 125 Elevation in Breast Cancer: A Case Report and Review of the Literature. The Breast Journal. 10(2). 146–149. 21 indexed citations

18.

Low, Jennifer A., Arlene Berman, Seth M. Steinberg, et al.. (2004). Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy. Journal of Clinical Oncology. 22(20). 4067–4074. 143 indexed citations

19.

Tan, Antoinette R., Xiaowei Yang, Stephen M. Hewitt, et al.. (2004). Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Journal of Clinical Oncology. 22(15). 3080–3090. 149 indexed citations

20.

Danforth, David N., Kenneth H. Cowan, Rosemary M. Altemus, et al.. (2003). Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial. Annals of Surgical Oncology. 10(6). 635–44. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact